While ADAR1 appears to act as an oncogenic driver through RNA-editing–dependent and independent mechanisms, ADARB2 in contrast emerges as a potential tumor suppressor, with its loss linked to enrichment of oncogenic pathways in our GSEA analyses. This evidence concerns the gene ADARB2 and neoplasm.